Duggan Robert W's Form 4 filing
Summit Therapeutics Inc. (SMMT) · filed Jun 12, 2026
- Accession no.
- 0001055919-26-000007
- Filed
- Jun 12, 2026
- Trade date
- Jun 12, 2026
- Filing delay
- Same day
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction. Open-market purchases total $50.0M. It was filed on the trade date.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Duggan Robert WCIK 0001055919 | Director, Officer (Co-Chief Executive Officer), 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 12, 2026 | Common Stock | PPurchaseAcquired | +3,810,000 | $13.12 | +$49,987,200 | 573,883,879 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.